Recombinant Herpes Zoster Vaccine | Shingrix - GSK

Advanced Shingles (Herpes Zoster) Immunization

When protecting adult patients—particularly those over 50 or immunocompromised individuals—against the painful and often debilitating effects of shingles (herpes zoster) and postherpetic neuralgia (PHN), healthcare providers require a state-of-the-art clinical intervention. The Herpes Zoster Vaccine (non-live recombinant, AS01B adjuvanted) (commercially recognized as Shingrix) provides unparalleled, active immunization designed strictly for intramuscular (IM) administration. Manufactured by GlaxoSmithKline (GSK), a global pioneer in advanced immunology, this two-component kit ensures the powerful clinical performance necessary for critical preventative healthcare protocols.

Why Choose Shingrix for Clinical Immunization?

Shielding patients from the reactivation of the varicella-zoster virus requires a highly targeted approach that overcomes the natural age-related decline in immunity. Instead of relying on traditional live-attenuated vaccines, Shingrix utilizes a breakthrough recombinant formulation paired with a proprietary AS01B adjuvant system. This specific combination is engineered to prompt an exceptionally robust and long-lasting CD4+ T-cell immune response, safely providing over 90% efficacy in preventing shingles across all studied age groups.

Key Product Specifications & Clinical Benefits

Two-Component System: Each kit is supplied with two critical vials that must be reconstituted together: one vial of lyophilized VZV gE antigen and one vial of AS01B Adjuvant Suspension.

Non-Live Recombinant: Offers a highly effective and safe profile, completely eliminating the risks associated with live virus vaccines, making it suitable for a wider range of patients.

Precise Single Dose: Once reconstituted, it provides exactly one 0.5 mL dose for clinical administration.

Targeted Administration: Formulated strictly for Intramuscular Injection, guaranteeing optimal absorption and systemic immune activation.

Essential Storage & Usage Guidelines

Maintaining the delicate biological integrity of this specialized recombinant vaccine is absolutely vital for its clinical efficacy.

Strict Cold Chain: Store both the lyophilized antigen vial and the liquid adjuvant vial strictly in a refrigerator between 2°C to 8°C.

Do Not Freeze: Freezing will irrevocably destroy the active vaccine structure. Discard immediately if either component has been frozen.

Preparation: The vaccine must be reconstituted by withdrawing the entire contents of the adjuvant vial and adding it to the lyophilized antigen vial. Shake gently to mix and administer immediately.

Important Notice: Shingrix is a Prescription Drug. It must be prescribed, handled, prepared, and administered strictly by a Registered Medical Practitioner in a clinical, pharmacy, or hospital setting. Keep all medicines safely out of the reach of children.